Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.37 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.37 |
| ▸ | OXTR | P30559 | 1/20 | 0.36 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL998346 | 1.00 | NNMT (0.42) | NNMTP2RX3MKNK1MKNK2CHRNA7 | |
| SCHEMBL998123 | 0.87 | NNMT (0.45) | NNMTP2RX3MKNK1MKNK2CHRNA7 | |
| SCHEMBL998124 | 0.87 | NNMT (0.45) | NNMTP2RX3MKNK1MKNK2CHRNA7 | |
| SCHEMBL14480161 | 0.87 | NNMT (0.45) | NNMTP2RX3MKNK1MKNK2CHRNA7 | |
| SCHEMBL4168613 | 0.81 | NNMT (0.42) | NNMTMKNK1MKNK2CHRNA7KMT2A | |
| SCHEMBL498475 | 0.81 | NNMT (0.42) | NNMTMKNK1MKNK2CHRNA7KMT2A | |
| SCHEMBL4572837 | 0.81 | NNMT (0.42) | NNMTMKNK1MKNK2CHRNA7KMT2A | |
| SCHEMBL4181664 | 0.81 | NNMT (0.42) | NNMTMKNK1MKNK2CHRNA7KMT2A | |
| SCHEMBL3727872 | 0.78 | NNMT (0.47) | NNMTMKNK1MKNK2CHRNA7KMT2A | |
| SCHEMBL19144265 | 0.78 | NNMT (0.41) | NNMTMKNK1MKNK2CHRNA7KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2136639-B1 | PYRID-2-YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2016-03-09 | — | — | EP | disclosed |
| US-8653091-B2 | Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof | EVOTEC AG (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20110009432-A1 | PYRID-2YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009432-A1 | PYRID-2YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | IL1B, C5, HTR2C | NNMT 1699/4885P2RX3 82/4885MKNK1 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.